TICKERNERD
Menu
KPRXKPRXHealthcare · Biotechnology

KPRX Stock Forecast: Kiora Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$2.59
−1.34% on the day

The 1 Wall Street analysts covering Kiora Pharmaceuticals, Inc. hold a median 12-month price target of $12 — +364.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 74 of 100 as at 22 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$11.8M
Ticker Nerd rank
74 / 100
Median analyst target
$12
Analysts covering
1
Total return, dividends reinvested
1W
+1.4%
1M
+2.2%
YTD
+31.2%
1Y
−1.3%
From 52W high
−9.6%
From 52W low
+43.6%
$1.80
$2.86
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

KPRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Kiora Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
74 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
92
Revisions
82
Volatility
79
Accruals
79
Growth
63
Momentum
56
Quality
51
Issuance
37
Value
8

Size (92): Smaller than most of the companies we track.

Value (8): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

KPRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on KPRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00Oct 25Jan 26Apr 26Jul 26KPRXHigh $12Median $12Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $12Median $12High $12

The green dot is the last close — the median target sits +364.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 Sept 2025HC Wainwright & Co.ReiteratesBuy—
2 Sept 2025HC Wainwright & Co.ReiteratesBuy$10
28 Mar 2025HC Wainwright & Co.ReiteratesBuy—
12 Nov 2024HC Wainwright & Co.ReiteratesBuy—
22 Aug 2024HC Wainwright & Co.ReiteratesBuy—
23 July 2024HC Wainwright & Co.MaintainsBuy—
20 May 2024HC Wainwright & Co.ReiteratesBuy—
27 Mar 2024HC Wainwright & Co.MaintainsBuy—
9 Feb 2024HC Wainwright & Co.MaintainsBuy—
13 Nov 2023HC Wainwright & Co.ReiteratesBuy—
6 Nov 2023HC Wainwright & Co.MaintainsBuy—
24 Aug 2023HC Wainwright & Co.ReiteratesBuy—
14 Aug 2023HC Wainwright & Co.MaintainsBuy—
9 Aug 2023Maxim GroupMaintainsBuy—
12 May 2023HC Wainwright & Co.MaintainsBuy—
24 Mar 2023HC Wainwright & Co.ReiteratesBuy—
9 Feb 2023Maxim GroupUpgradeBuy—
8 Feb 2023HC Wainwright & Co.ReiteratesBuy—
8 Feb 2023Ladenburg ThalmannReiteratesBuy—
25 Aug 2022Ladenburg ThalmannInitiatesBuy$6.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KPRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

KPRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Kiora Pharmaceuticals, Inc. (KPRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
3.7×

Cheaper than 68% of US stocks

Price / sales
—
Price / book
0.8×

Cheaper than 80% of US stocks

EV / EBITDA
0.5×

Cheaper than 58% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−56.4%

Higher than 20% of US stocks

Return on assets
−21.9%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

KPRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
KPRXKiora Pharmaceuticals, Inc.$11.8M
74
PDSBPDS Biotechnology Corp.$12.0M
59
MBRXMoleculin Biotech, Inc.$11.6M
21
SNTISenti Biosciences Holdings, Inc.$12.1M
56
GDTCCytoMed Therapeutics Ltd.$12.2M
17
ASBPAspire Biopharma Holdings, Inc.$11.2M
15
INABIN8bio, Inc.$12.5M
43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Kiora Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest KPRX news & analysis

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

Newsfile Corp · 19 Aug 2026positive

Kiora Pharmaceuticals announced it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporation, a leading South Korean pharmaceutical company based in Seoul.

Why it matters — This expands the potential development and commercialization reach of Kiora's KIO-301 by partnering with an established pharmaceutical company in the South Korean market.

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Newsfile Corp · 7 Aug 2026positive

Kiora Pharmaceuticals reported its second-quarter 2026 financial results, highlighting advanced enrollment into the higher-dose cohort of the Phase 2 ABACUS-2 trial of KIO-301 and continued enrollment in the higher-dose cohort of the Phase 2 KLARITY trial of KIO-104. The company ended the quarter with about $16.8 million in cash and short-term investments, providing an expected operating runway into late 2028, and secured a private placement of up to $24.0 million in gross proceeds.

Why it matters — This update shows pipeline progress in both Phase 2 trials and a funding runway into late 2028, giving KPRX watchers a view of the company's clinical and financial position.

FAQ

Frequently asked questions about KPRX stock

What is the KPRX stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Kiora Pharmaceuticals, Inc. have a median 12-month price target of $12, with estimates ranging from $12 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is KPRX stock a buy right now?

Of the 1 analysts covering Kiora Pharmaceuticals, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kiora Pharmaceuticals, Inc. 74 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank KPRX?

As at 22 Aug 2026, Kiora Pharmaceuticals, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).

Will KPRX stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +364.2% from the last close, and Ticker Nerd's factor model ranks Kiora Pharmaceuticals, Inc. 74 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the KPRX stock forecast for 2030?

No analyst covering Kiora Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KPRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.

How has KPRX stock performed over the past year?

Kiora Pharmaceuticals, Inc. returned -1.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Kiora Pharmaceuticals, Inc. do?

Kiora Pharmaceuticals Inc. is a biotechnology company focused on developing and commercializing therapies for eye disease.

What is the latest news on KPRX?

The most recent item we track (Newsfile Corp, 19 Aug 2026): "Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation". Kiora Pharmaceuticals announced it has licensed the development and commercialization rights for KIO-301 in South Korea for ophthalmic indications to Chong Kun Dang Pharmaceutical Corporation, a leading South Korean pharmaceutical company based in Seoul.

Company

About Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals Inc. is a biotechnology company focused on developing and commercializing therapies for eye disease. The company primarily works on innovative treatments aimed at addressing unmet medical needs in ophthalmology. Their research and product development are directed towards advancing therapies that can combat vision-related ailments such as eye inflammation and retinal diseases. By specializing in niche and complex eye conditions, Kiora Pharmaceuticals impacts the biotechnology and healthcare sectors, offering potential breakthroughs and improvements in treatment options. The company's commitment to biotechnology innovation provides vital contributions to therapeutic development within the pharmaceutical landscape, emphasizing targeted, patient-centric approaches in vision care.

CEO Dr. Brian M. Strem Ph.D. · 13 employees · United States · https://www.kiorapharma.com